Challenging Genitourinary Tumors: What's New in 2017

Challenging Genitourinary Tumors: What's New in 2017

In reviewing the genitourinary malignancies in the context of recent findings from ASCO 2017, David J. Vaughn, MD, focuses on studies that are, or have become, standards of care. These include abiraterone acetate as an adjunct to androgen-deprivation in high-risk metastatic castration-sensitive prostate cancer; the immune checkpoint inhibitors for patients with metastatic urothelial carcinoma following platinum chemotherapy; and surgery alone for high-risk kidney cancer, following the failure of adjuvant tyrosine inhibitor therapy to demonstrate efficacy in the PROTECT trial.

 
Related Links:

Published

November 17, 2017

Created by

Penn Physician VideoLink